MSLE ▲ +0.8% - Satellos Bioscience Inc. $MSLE - Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback 06-NOV-2026 07:00 AM ET